Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III registration trial to reduce the risk of contracting travelers' diarrhea in the United States, and Phase II field trial for Travelers' Diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in Phase I/IIa clinical trial for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.

Metric
Company Name	Immuron Limited
Symbol	IMC
MSH ID	AU:COM:IMMURON
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	AU
Stage
Employee Count	6
Website	immuron.com.au
LinkedIn
Founders

Metric
Market Cap	12.38M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	3.13M
Revenue (LTM)
Revenue (NTM)
Gross Profit	2.13M
EBITDA	-6.44M
Operating Income	-5.51M
Net Income	-4.43M
EPS	-0.02
Diluted EPS	-0.02
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.69
Operating Profit Margin	-1.54
EBITDA Margin	-2.06
Net Profit Margin	-1.09
Return on Equity	-0.21
Return on Assets	-0.20
Return on Capital Employed	-0.36

AU:COM:IMMURON

Immuron Limited

Last Close

0.07

24/11 23:26

Market Cap

19.38M

Beta: -

Volume Today

117.79K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-4.51
P/B Ratio	0.87
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	7.01
EV Multiple	-3.74

Metric
Days Sales Outstanding	84.42
Days Payables Outstanding	1.76K
Days Inventory Outstanding	530.20
Operating Cycle	587.29
Cash Conversion Cycle	321.39
Asset Turnover	0.32

Metric
Operating Cash Flow	-3.55M
Free Cash Flow	-3.55M
Cash Flow to Debt
Operating Cash Flow/Sales	-0.95
Free Cash Flow Yield	-0.15

Metric
Cash & Equivalents	7.45M
Accounts Receivable
Inventory	1.01M
Goodwill
Debt to Capitalization	0.01
Debt to Assets	0.01
Current Ratio	9.20
Quick Ratio	7.79

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.13
R&D to Revenue	1.44
SG&A to Revenue	2.34